ORG
AstraZeneca’s Calquence Combo Approved for First-Line CLL in EU
AstraZeneca; Calquence; EU approval; chronic lymphocytic leukaemia; first-line treatment; venetoclax; obinutuzumab; BTK inhibitor; Amplify trial
EMA Identifies Very Rare Eye Condition as Side Effect of Semaglutide
EMA; semaglutide; rare side effect; NAION; vision loss; Ozempic; Wegovy; Rybelsus
MIT’s Boltz-1 AI Model Rivals AlphaFold 3 in Biomolecular Structure Prediction
MIT; Boltz-1; AlphaFold 3; AI model; biomolecular structure prediction; drug discovery; protein folding; open-source AI
Otsuka’s Phase 3 IgAN Win with Sibeprenlimab Shakes Vera’s Stock
Otsuka; sibeprenlimab; IgA nephropathy; phase 3 trial; proteinuria reduction; Vera Therapeutics; stock drop; kidney disease; UPCR; FDA Priority Review
GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs
GSK; Sanofi; vaccine R&D; Sanjay Gurunathan; leadership change; pharmaceutical industry; Bristol Myers Squibb; corporate affairs; executive appointment
Biotech Leaders Urge FDA to ‘Modernise’ Regulation to Compete with China
FDA; biotech; regulation; modernization; China; cell and gene therapy; CEO roundtable; competitiveness; innovation
23andMe to Restart Auction After Former CEO Anne Wojcicki Outbids Regeneron
23andMe; auction; Anne Wojcicki; Regeneron; TTAM Research Institute; bankruptcy; asset sale; genetics
Corcept Highlights Survival Benefit Despite ALS Trial’s Missed Primary Endpoint
Corcept Therapeutics; dazucorilant; ALS; amyotrophic lateral sclerosis; DAZALS trial; survival benefit; phase 2 study; ALSFRS-R; ENCALS 2025
Schott Pharma Invests Over €100M in New Sterile Cartridge Facility at Hungary Site
Schott Pharma; Hungary; sterile cartridge facility; €100 million investment; RTU cartridges; pharma packaging; manufacturing expansion; Lukácsháza; GLP-1 drugs; diabetes; automation; environmental impact
Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio
Cullinan Therapeutics; Genrix Bio; BCMA bispecific; velinotamig; T-cell engager; autoimmune disease; CD19xCD3; CLN-978; multiple myeloma; clinical development; biotech partnerships